Table 1 Demographic and clinical variables of study cohort

Age (years)

62 (55,69)

58 (52, 65)*

68 (61, 75)*†

Gender(% female)

28 (33.73)

49 (32.88)

24 (36.36)

BMI(kg/m²)

24.2 (22.6, 26.5)

24.3 (22.5, 26.4)*

24.0 (22.9, 26.3)

Restheart rate (bpm)

76 (67, 86)

75 (65, 84)

77 (70, 88)

SBP (mmHg)

120.0 (116.0, 124.0)

128.0 (116.0, 140.0)*

128.0 (118.0, 140.5)*

DBP (mmHg)

79.0 (70.0, 87.0)

78.00 (70.0, 87.0)

80.0 (70.0, 87.0)

Fasting plasma glucose, mmol/l

–

8.59 (6.42, 10.65)

6.97 (5.87, 9.10)†

HbA1c (%)

–

7.20 (6.60, 8.28)

6.70 (6.40, 7.15)†

Diabetes duration (year)

–

7.25 (4.00, 12.00)

8.50 (3.50, 12.00)

TG (mmol/l)

–

1.37 (1.05, 2.00)

1.29 (1.10, 1.60)

TC (mmol/l)

–

4.24 (3.54, 5.07)

3.72 (3.14, 4.79)

HDL (mmol/l)

–

1.09 (0.87, 1.35)

1.21 (1.02, 1.48)

LDL (mmol/l)

–

2.42 ± 0.96

2.23 ± 0.81

Regurgitation degree

 Mild, n (%)

–

–

29 (43.9)

 Moderate, n (%)

–

–

20 (30.3)

 Severe, n (%)

–

–

17 (25.8)

Diabetes related drugs

 Biguanides, n (%)

–

37 (33.6)

10 (15.2)

 Sulfonylureas, n (%)

–

21 (19.2)

19 (28.8)

 α-Glucosides inhibitor, n (%)

–

24 (21.8)

20 (30.3)

 GLP-1/DPP-4 inhibitor

–

7 (6.4)

5 (7.6)

 Insulinum

–

14 (12.7)

12 (18.1)

 Medication unknown

–

7 (6.3)

0

 eGFR (mL/min)

–

72.3 ± 29.3

67.5 ± 19.7